Man thinking

Lenabasum receives Orphan Drug Designation for DM

Corbus Pharmaceuticals recently announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation to lenabasum, its novel, synthetic oral endocannabinoidmimetic drug, for the treatment of dermatomyositis, systemic sclerosis, and other conditions.

Continue Reading

TMA in 25 Words

May is Myositis Awareness Month. This year, TMA also celebrates 25 years as Your Myositis Association. In recognition of this amazing achievement in the rare disease world, TMA invited its members to  describe TMA in 25 words (more or less).

Continue Reading